



**MYELOMA
CANADA**
MAKING MYELOMA MATTER

Saskatchewan approves Velcade® (bortezomib) for first line treatment in newly-diagnosed transplant-eligible patients

January 2012

The Saskatchewan Cancer Agency has announced its approval of front-line funding for Velcade® (bortezomib) in newly-diagnosed multiple myeloma patients who are eligible for high-dose chemotherapy (stem cell transplant) treatment.

The latest Saskatchewan formulary includes the use of Velcade® (bortezomib) as induction treatment for multiple myeloma as part of an approved regimen in patients who are eligible for a stem cell transplant.

Myeloma Canada continues its advocacy efforts for broader coverage in the remaining provinces to ensure patients have access to new myeloma treatment options.

To access the Saskatchewan Drug Formulary, please [click here](#)